DeBakey Veterans Affairs Medical Center which is financing the study. Jose M. Duncan Cancer Center and the Huffington Focus on Aging at Baylor College of Medication and Michael E. Juergen Engel, PhD, CEO and President of Aeterna Zentaris mentioned, ‘This is a key study as it allows us to venture into the field of cancer-cachexia, a sign with high unmet medical requirements. Because cachexia is extremely common among cancer sufferers, our oral ghrelin agonist, AEZS-130, could represent a novel treatment choice for many of the 1.S.Adherence to twice daily acyclovir was high, with 88 percent of doses dispensed , and 96 percent of dispensed dosages used, as measured by pill counts. Retention of study participants at 24 months of follow-up was 92 percent for HIV infected partners and 84 percent for HIV uninfected partners. The Companions in Prevention HSV/HIV Transmission Study is the first scientific trial to directly test whether suppressing HSV-2 illness in HIV-infected persons could reduce rates of HIV transmission and HIV disease progression.